Seasonal influenza is responsible for 200 000 to 400 000 hospitalizations and 20 000 to 40 000 deaths annually in the United States.1 At present, the cornerstone of influenza control is vaccination. Groups recommended by the Advising Committee on Immunization Practices (ACIP) to be vaccinated yearly include all adults older than 50 years, children aged 6 to 23 months, chronically ill persons, and health care workers. Although an effective live attenuated vaccine is approved for persons aged 5 to 49 years, trivalent inactivated vaccine (TIV) remains the primary method of vaccination for the majority of at-risk populations. The production of adequate supplies of yearly influenza vaccine is challenging for a number of reasons, including the need to anticipate new circulating strains in advance, adaptation of new variants for growth in embryonated hens' eggs, and an expanding target population. These issues are further complicated by the exodus of US vaccine manufacturers. In 1967, 26 companies made vaccines for the US market; today, few remain.2 Not surprisingly, 2 major interruptions with influenza vaccine production have occurred in the last 8 years. In 2000-2001, a significant delay in vaccine production occurred, and although the full complement of vaccine was eventually distributed, a considerable disruption in care resulted. During 2004-2005, vaccine lots produced at a Chiron Corp production facility had evidence of contamination with the bacteria Serratia marcescens. The plant was closed temporarily, resulting in a loss of nearly half the planned one hundred million doses for US distribution. As a result, healthy persons were asked to forgo vaccination and high-risk individuals were strategically prioritized.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.